This study underscores the significant interpatient variation in the PK of FVIII concentrates in Korean patients with hemophilia A. To optimize the effectiveness of prophylactic regimens and improve the overall treatment outcomes, a personalized approach must be implemented and tailored according to an individual patient’s PK profile. The gene discussed is F8; the disease is hemophilia A.